fluasterone also known fluorinated synthetic analogue dehydroepiandrosterone dhea investigation aeson therapeutics variety therapeutic indications including cancer cardiovascular diseases diabetes obesity traumatic brain injury among others ultimately never modification dhea hydroxyl removed hydrogen atom substituted fluorine atom position fluasterone reached phase ii clinical trials prior discontinuation mechanism action dhea fluasterone however similarly dhea strongly fluasterone potent uncompetitive inhibitor dehydrogenase ki μm versus μm drug retains antiinflammatory antihyperplastic chemopreventative antihyperlipidemic antidiabetic antiobesic well certain immunomodulating activities dhea much thought may possibly mediated via inhibition experimental evidence support notion conversely unlike dhea fluasterone minimal androgenic estrogenic activity due presence fluorine atom position metabolism position sterically hindered thus metabolized androgens like testosterone estrogens like also contrast dhea fluasterone produce sedation seizures animals hence thought interact gabaa addition unlike dhea fluasterone reduced effects peroxisome proliferator ie lacks activity pparαtooltip peroxisome proliferatoractivated receptor alpha hence pose risk liver toxicities hepatomegaly hepatocellular reasons fluasterone developed considered advantageous due extensive firstpass hepatic andor gastrointestinal metabolism high doses dhea fluasterone necessary animals efficacy fluasterone increased administered parenterally reason nonoral formulation fluasterone selected clinical however development fluasterone nonetheless stopped reportedly due low potency low oral bioavailability said rendered unsuitable clinical httpsenwikipediaorgwikifluasterone